| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 300049 from our risk checks.
Inner Mongolia Furui Medical Science Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥40.11 |
| 52 Week High | CN¥57.50 |
| 52 Week Low | CN¥27.28 |
| Beta | -0.38 |
| 11 Month Change | -10.97% |
| 3 Month Change | -24.86% |
| 1 Year Change | 42.49% |
| 33 Year Change | 212.63% |
| 5 Year Change | 379.78% |
| Change since IPO | 75.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300049 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.0% | 0.2% | 0.6% |
| 1Y | 42.5% | -8.9% | -19.1% |
Return vs Industry: 300049 exceeded the CN Pharmaceuticals industry which returned -8.9% over the past year.
Return vs Market: 300049 exceeded the CN Market which returned -19.1% over the past year.
Price Volatility
| 300049 volatility | |
|---|---|
| 300049 Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in CN Market | 8.8% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 300049's share price has been volatile over the past 3 months.
Volatility Over Time: 300049's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 703 | Guanyi Wang | www.fu-rui.com |
Inner Mongolia Furui Medical Science Co., Ltd. engages in the production and sale of pharmaceutical drugs in China and internationally. It operates in two segments, pharmaceutical production and sales; and diagnostic equipment R&D, production and sales.
Inner Mongolia Furui Medical Science Co., Ltd. Fundamentals Summary
| 300049 fundamental statistics | |
|---|---|
| Market cap | CN¥10.67b |
| Earnings (TTM) | CN¥133.11m |
| Revenue (TTM) | CN¥1.27b |
75.4x
P/E Ratio7.9x
P/S RatioIs 300049 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300049 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.27b |
| Cost of Revenue | CN¥329.35m |
| Gross Profit | CN¥942.53m |
| Other Expenses | CN¥809.42m |
| Earnings | CN¥133.11m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.50 |
| Gross Margin | 74.11% |
| Net Profit Margin | 10.47% |
| Debt/Equity Ratio | 0% |
How did 300049 perform over the long term?
See historical performance and comparison